

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

204311Orig1s000

Trade Name: Abacavir and Lamivudine Tablets for Oral Suspension,
60 mg/30 mg

Generic or Proper Name: Abacavir and Lamivudine Tablets for Oral Suspension,
60 mg/30 mg

Sponsor: Mylan Pharmaceuticals Inc., a Viatris Company

Approval Date: December 22, 2023

Indication: Abacavir and Lamivudine Tablets for Oral Suspension,
60 mg/30 mg is indicated in combination with other
antiretroviral agents for the treatment of HIV-1 infection
in pediatric patients 3 months of age and older and
weighing at least 5 kg

CENTER FOR DRUG EVALUATION AND RESEARCH

204311Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	X
Labeling	X
REMS	
Summary Review	X
Officer/Employee List	X
Office Director Memo	
Cross Discipline Team Leader Review	
Clinical Review(s)	X
Product Quality Review(s)	X
Non-Clinical Review(s)	X
Statistical Review(s)	
Clinical Microbiology / Virology Review(s)	
Clinical Pharmacology Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	
Administrative/Correspondence Document(s)	

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

204311Orig1s000

APPROVAL LETTER



NDA 204311

NDA APPROVAL

Mylan Pharmaceuticals Inc., a Viatris Company
U.S. Agent for Mylan Laboratories Limited, a Viatris Company, India
Attention: Beth Britton
Head of Regulatory Affairs U.S. Generics
3711 Collins Ferry Road
Morgantown, WV 26505

Dear Ms. Britton:

Please refer to your new drug application (NDA) dated and received December 23, 2013, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for the following drug product:

- Abacavir and Lamivudine Tablets for Oral Suspension, 60 mg/30 mg

We acknowledge receipt of your amendment dated July 15, 2022, and June 22, 2023, which constituted complete responses to our August 6, 2019, and January 13, 2023, complete response letters, respectively.

We acknowledge receipt of your amendment dated February 6, 2019, following our October 23, 2014, tentative approval letter.

This NDA provides for the use of Abacavir and Lamivudine Tablets for Oral Suspension, 60 mg/30 mg in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients 3 months of age and older and weighing at least 5 kg. Information related to Abacavir and Lamivudine Tablets for Oral Suspension, 60 mg/30 mg intended for use under the President's Emergency Plan for AIDS Relief (PEPFAR) program was also included in this submission.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, Warning Card, and Medication Guide) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 204311.**” Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

Based on the stability data submitted to-date, the expiry dating period for Abacavir and Lamivudine Tablets for Oral Suspension, 60 mg/30 mg shall be 24 months from the date of manufacture in HDPE bottles containing 60 tablets with induction seal and a child-resistant cap when stored below 30°C (86°F).

MARKET PACKAGE

Please submit one market package of the drug product when it is available to the

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

following address:

Monica Zeballos
Food and Drug Administration
Center for Drug Evaluation and Research
White Oak Building 22, Room: 6330
10903 New Hampshire Avenue
Silver Spring, Maryland
Use zip code **20903** if shipping via United States Postal Service (USPS).
Use zip code **20993** if sending via any carrier other than USPS (e.g., UPS, DHL, FedEx).

PROPRIETARY NAME

If you intend to have a proprietary name for this product, the name and its use in the labeling must conform to the specifications under 21 CFR 201.10 and 201.15. We recommend that you submit a request for a proposed proprietary name review. (See the guidance for industry *Contents of a Complete Submission for the Evaluation of Proprietary Names*, and *PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2023 through 2027*.)

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement in patients less than 3 months of age because this product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients and is unlikely to be used in a substantial number of pediatric patients less than 3 months of age.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standards for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website⁶.

If you have any questions, call Monica Zeballos, Sr. Program Consultant, at (301) 796-0840.

Sincerely yours,

{See appended electronic signature page}

Sarita Boyd, Pharm.D.
Associate Director for PEPFAR
Division of Antivirals
Office of Infectious Diseases
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide
 - Instructions for Use
 - Warning Card

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

⁶ <https://www.uspnf.com/>

- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

SARITA D BOYD
12/22/2023 04:12:59 PM